Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis.
Casadei-Gardini A, Scartozzi M, Tada T, Yoo C, Shimose S, Masi G, Lonardi S, Frassineti LG, Nicola S, Piscaglia F, Kumada T, Kim HD, Koga H, Vivaldi C, Soldà C, Hiraoka A, Bang Y, Atsukawa M, Torimura T, Tsuj K, Itobayashi E, Toyoda H, Fukunishi S, Rimassa L, Rimini M, Cascinu S, Cucchetti A.
Casadei-Gardini A, et al. Among authors: rimini m.
Liver Int. 2021 Jun;41(6):1389-1397. doi: 10.1111/liv.14817. Epub 2021 Feb 20.
Liver Int. 2021.
PMID: 33547848